Module 1: Regulatory Considerations for Specialty Oncology Biotherapeutics

Recorded On: 05/04/2023

image
image


There is more than one regulatory guideline that needs to be taken into consideration depending on the therapeutic modality of a biotherapeutic being developed for oncology indications. Protein-based biotherapeutics generally fall under one set of regulatory guidelines, while cell and gene therapy products fall under a different set. There are several key differences in the regulatory requirements for oncology versus nononcology indications, biotherapeutics versus small molecules, and protein biotherapeutics vs cell and gene therapies. This presentation will give an overview of the primary regulatory guidelines for the different modalities as well as highlight the similarities and differences in approaches to developing a nonclinical strategy to fulfill regulatory expectations for each type of modality. In the last few years, non-human primates (NHPs) have been in high demand, and a critical shortage of animals has developed worldwide. Considerations around the use of non-human primates (NHPs) will be discussed including: 1) if certain types NHP studies are always needed; 2) strategies that include not conducting toxicity studies in NHPs if rodents are pharmacologically relevant, and development programs where there are no pharmacologically relevant species, including NHPs.

Marque Todd, DVM, DABT

Marque Todd, DVM, DABT

Consultant

Renaissance Consulting

Dr. Marque Todd is a board-certified regulatory toxicology expert. Dr. Todd trained as a veterinarian and completed post-doctoral work in molecular immunology and cancer biology. She has more than 25 years of experience working in the biopharmaceutical industry. Dr. Todd has extensive nonclinical development experience with a variety of biologic modalities including monoclonal antibodies, bi-specific antibodies, Fc and other fusion proteins, antibody-drug conjugates, cytokines/interleukins, protein replacement therapies, nanoparticles, cell therapies, oncolytic viruses, and therapeutic vaccines. Dr. Todd has been involved in the preparation and submission of nonclinical sections of early and late-stage regulatory documents including INDs and BLAs/NDAs and has participated in numerous successful health authority meetings.

Dr. Todd is currently a regulatory toxicology consultant to several large, mid-size and small biopharma companies. Prior to becoming an independent consultant, Dr. Todd was a Research Fellow at Pfizer and served as a Principal Scientist at Amgen and Chiron. Dr. Todd also served as an Adjunct Professor with the University of California San Diego Extension, where she co-taught a course on nonclinical toxicology and drug development with sessions focused on the nonclinical development of biotherapeutics and oncology products.

Key:

Complete
Failed
Available
Locked
Module 1 Regulatory Considerations for Specialty Oncology Biotherapeutics
Module 1: Regulatory Considerations for Specialty Oncology Biotherapeutics, Marque Todd, DVM, DABT
Recorded 05/04/2023  |  90 minutes
Recorded 05/04/2023  |  90 minutes As part of your registration, you will have unlimited access to the module recording for 30 days. Your 30-day access period begins when you first access the recording. Once the access period begins, it cannot be reset or restarted. To receive a certificate of completion, you must watch the recording for the minimum required viewing time. Please keep the recording open while viewing, as the system tracks your viewing time during the active session. If you close your browser before meeting the minimum viewing requirement, your viewing progress may not be retained. Once you have met the viewing requirement, the module survey will become available. After completing the survey, you will be able to access and download your certificate of completion. If you have any questions, please contact ACT Headquarters at [email protected].
Survey
13 Questions
13 Questions ACT values your feedback. Please help us continue to provide high-quality educational offerings by completing this short survey. The survey will become available after you have met the minimum viewing requirement for the recording. Once you complete the survey, your certificate of completion will become available on your dashboard or for download.
Certificate
No credits available  |  Certificate available
No credits available  |  Certificate available Your certificate of completion will become available after you have met the minimum viewing requirement and completed the module survey.